Price Alert

Organon & Co. (OGN)

NYSE: OGN · Real-Time Price · USD

10.12

-0.29 (-2.79%)

At close: Sep 25, 2025, 3:59 PM

10.07

-0.49%

After-hours: Sep 25, 2025, 05:20 PM EDT

-2.79% (1D)

Bid	10.06
Market Cap	2.63B
Revenue (ttm)	6.28B
Net Income (ttm)	700M
EPS (ttm)	2.69
PE Ratio (ttm)	3.76
Forward PE	2.61
Analyst	Buy
Dividends	$0.88

Ask	10.3
Volume	2,632,102
Avg. Volume (20D)	4,089,976
Open	10.35
Previous Close	10.41
Day's Range	10.05 - 10.38
52-Week Range	8.01 - 19.41
Beta	0.56
Ex-Dividend Date	Aug 15, 2025

About OGN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol OGN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for OGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Organon & Co. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-13.13%

OGN stock has given up its prior gain. Organon sha... Unlock content with Pro Subscription

1 month ago

-13.13%

Organon shares are trading higher after the company beat Q2 estimates and raised FY25 guidance.

News

1 day ago · zacks.com

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

1 day ago · accessnewswire.com

Orogen Royalties' Exploration Stage Project and Royalty Update

VANCOUVER, BC / ACCESS Newswire / September 24, 2025 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage...

6 days ago · zacks.com

Organon (OGN) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Organon (OGN) stood at $10.45, denoting a -3.69% move from the preceding trading day.

6 days ago · businesswire.com

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--European Commission Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars.

1 week ago · zacks.com

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

2 weeks ago · zacks.com

Organon (OGN) Stock Declines While Market Improves: Some Information for Investors

Organon (OGN) concluded the recent trading session at $10.26, signifying a -1.06% move from its prior day's close.

2 weeks ago · accessnewswire.com

Orogen Royalties Announces Trading on the OTCQB

VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce its shares have been qualified to begin trading o...

3 weeks ago · accessnewswire.com

Orogen Royalties and South32 Form Generative Base Metals Alliance

All dollar figures expressed in United States dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / September 4, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Compan...

3 weeks ago · businesswire.com

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).

1 month ago · accessnewswire.com

Orogen Royalties Reports Q2 2025 Financial Results Based on Carve-out Financial Statements

VANCOUVER, BC / ACCESS Newswire / August 26, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. (formerly 1537944 BC Ltd.) ("Orogen" or the "Company") is pleased to announce strong revenue and cash fl...

Load More News